No Survival Benefit in Advanced Breast Cancer With Frontline CDK4/6 Inhibition

(MedPage Today) — Frontline treatment with a CDK4/6 inhibitor did not improve overall survival (OS) in advanced hormone receptor (HR)-positive/HER2-negative breast cancer compared with second-line treatment, updated results from a randomized trial…

Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/119981

Author :

Publish date : 2026-02-20 22:12:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

No Survival Benefit in Advanced Breast Cancer With Frontline CDK4/6 Inhibition

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

What to Know About ALS After Actor Eric Dane’s Death

Related Posts

FDA Approves First Non-Antipsychotic Drug for Alzheimer’s Agitation

Novel Pulsed Field Ablation System Turns to High-Energy, Ultra-Short Zaps

US Court Blocks Mail-order Access to Abortion Drugs, for Now

Study Examines if Prenatal Exposure to Sedatives Is Linked to Psych Disorders

FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

FDA Approves First Non-Antipsychotic Drug for Alzheimer’s Agitation

Novel Pulsed Field Ablation System Turns to High-Energy, Ultra-Short Zaps

US Court Blocks Mail-order Access to Abortion Drugs, for Now

Study Examines if Prenatal Exposure to Sedatives Is Linked to Psych Disorders

FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

As RFK Jr. Downplays Rabies, CDC Staff Tells Docs It’s a Daily Threat

Which Former NIH Official Was Indicted?

Categories

Archives